5 completed. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 5 |
Follow Multi-centric Castleman's Disease: new trials by email Literature Review of Multi-centric Castleman's Disease trials Research Report on Multi-centric Castleman's Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in Malawi Rituximab, Etoposide - Multicentric Castleman Disease | Phase 2 | Completed | UNC Lineberger Comprehensive Cancer Center | 15 | 2021-06-22 | 2026-07-30 |
| Tocilizumab for KSHV-Associated Multicentric Castleman Disease Zidovudine, Tocilizumab, Valganciclovir (VGC) - Castleman Disease, Multicentric Castleman Disease | Phase 2 | Completed | National Cancer Institute (NCI) | 8 | 2011-09-13 | 2020-10-27 |
| A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease Siltuximab - Multicentric Castleman's Disease | Phase 2 | Completed | Janssen Research & Development, LLC | 60 | 2011-04-01 | 2018-05-22 |
| A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease Siltuximab, Placebo, Best Supportive Care (BSC) - Multicentric Castleman's Disease | Phase 2 | Completed | Janssen Research & Development, LLC | 79 | 2010-03-18 | 2018-03-21 |
| 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis tanespimycin - Chronic Myeloproliferative Disorders, Leukemia | Phase 2 | Completed | National Institutes of Health Clinical Center (CC) | 37 | 2006-05-01 | 2012-03-15 |
Macular dystrophy, corneal type 1 (2) · Acquired Immunodeficiency Syndrome (1) · Angiolymphoid Hyperplasia with Eosinophilia (1) · Burkitt Lymphoma (1) · Castleman Disease (1) · Leukemia (1) · Leukemia, Hairy Cell (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Large-Cell, Immunoblastic (1) · Lymphoma, Mantle-Cell (1)
DNA Virus Infections (2) · Hemic and Lymphatic Diseases (2) · Herpesviridae Infections (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Infections (2) · Lymphatic Diseases (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Virus Diseases (2) · Blood Coagulation Disorders (1) · Blood Platelet Disorders (1) · Blood Protein Disorders (1) · Blood-Borne Infections (1)
siltuximab (2) · Etoposide (1) · Rituximab (1) · Valganciclovir (1) · Zidovudine (1) · tanespimycin (1) · tocilizumab (1)
Janssen Research & Development, LLC (2) · National Cancer Institute (NCI) (1) · National Institutes of Health Clinical Center (CC) (1) · UNC Lineberger Comprehensive Cancer Center (1)
United States (4) · Belgium (2) · Brazil (2) · Canada (2) · China (2) · Egypt (2) · France (2) · Germany (2) · Hong Kong (2) · Israel (2) · New Zealand (2) · Norway (2) · Singapore (2) · South Korea (2) · Spain (2)
Antonio T. Fojo, MD, PhD (1) · Robert Yarchoan, M.D. (1) · Yuri Fedoriw, MD (1)
PMID 25042199, PMID 28087540, PMID 32276276, PMID 35793409
2009 (1), K01TW011470 (1)